AbCellera Biologics Inc. (NASDAQ:ABCL) COO Veronique Lecault Acquires 200,000 Shares

AbCellera Biologics Inc. (NASDAQ:ABCLGet Rating) COO Veronique Lecault acquired 200,000 shares of AbCellera Biologics stock in a transaction that occurred on Monday, May 16th. The shares were purchased at an average price of $6.34 per share, for a total transaction of $1,268,000.00. Following the transaction, the chief operating officer now directly owns 1,770,122 shares in the company, valued at $11,222,573.48. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Veronique Lecault also recently made the following trade(s):

  • On Monday, February 28th, Veronique Lecault bought 230,789 shares of AbCellera Biologics stock. The shares were bought at an average cost of $8.66 per share, for a total transaction of $1,998,632.74.

Shares of NASDAQ:ABCL traded up $0.20 during midday trading on Tuesday, reaching $8.01. The company’s stock had a trading volume of 82,872 shares, compared to its average volume of 2,009,382. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of 12.56 and a beta of -0.26. The firm has a 50 day moving average price of $8.50 and a two-hundred day moving average price of $10.90. AbCellera Biologics Inc. has a fifty-two week low of $5.42 and a fifty-two week high of $36.05.

AbCellera Biologics (NASDAQ:ABCLGet Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.16. The business had revenue of $316.58 million during the quarter, compared to analyst estimates of $208.96 million. During the same period in the prior year, the firm earned $0.37 earnings per share. The firm’s revenue for the quarter was up 56.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that AbCellera Biologics Inc. will post 0.48 EPS for the current year.

A number of institutional investors have recently modified their holdings of ABCL. Baillie Gifford & Co. increased its position in AbCellera Biologics by 209.2% in the 1st quarter. Baillie Gifford & Co. now owns 11,048,765 shares of the company’s stock valued at $107,725,000 after buying an additional 7,474,857 shares in the last quarter. Capital World Investors increased its position in AbCellera Biologics by 47.8% in the 3rd quarter. Capital World Investors now owns 19,821,407 shares of the company’s stock valued at $397,221,000 after buying an additional 6,405,970 shares in the last quarter. Lazard Asset Management LLC increased its position in AbCellera Biologics by 997.1% in the 1st quarter. Lazard Asset Management LLC now owns 3,189,837 shares of the company’s stock valued at $31,100,000 after buying an additional 2,899,091 shares in the last quarter. Renaissance Technologies LLC increased its position in AbCellera Biologics by 385.5% in the 1st quarter. Renaissance Technologies LLC now owns 2,617,603 shares of the company’s stock valued at $25,522,000 after buying an additional 2,078,400 shares in the last quarter. Finally, BlackRock Inc. increased its position in AbCellera Biologics by 142.4% in the 4th quarter. BlackRock Inc. now owns 2,367,242 shares of the company’s stock valued at $33,852,000 after buying an additional 1,390,655 shares in the last quarter. 39.58% of the stock is owned by institutional investors and hedge funds.

Several research analysts have commented on ABCL shares. BMO Capital Markets reaffirmed a “buy” rating and set a $40.00 target price on shares of AbCellera Biologics in a report on Wednesday, May 11th. SVB Leerink cut their target price on AbCellera Biologics from $25.00 to $20.00 and set an “outperform” rating on the stock in a report on Friday, February 25th. Piper Sandler cut their target price on AbCellera Biologics from $28.00 to $21.00 in a report on Wednesday, May 11th. Zacks Investment Research downgraded AbCellera Biologics from a “buy” rating to a “hold” rating in a report on Wednesday, May 11th. Finally, Credit Suisse Group lifted their target price on AbCellera Biologics from $39.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, February 25th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $26.08.

About AbCellera Biologics (Get Rating)

AbCellera Biologics Inc develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners.

Read More

Insider Buying and Selling by Quarter for AbCellera Biologics (NASDAQ:ABCL)

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.